Skip to content

Effect of Rapeseed Oil and Sunflower Oil

Effect of a Diet With Rapeseed Oil /Sunflower Oil on Lipoprotein in Children and Adolescents With Familial Hypercholesterolemia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00924274
Enrollment
24
Registered
2009-06-18
Start date
2008-03-31
Completion date
2010-12-31
Last updated
2009-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hypercholesterolemia

Brief summary

Familial hypercholesterolemia (FH), an inherited disorder of lipoprotein metabolism, is a risk for early cardiovascular disease (CVD). This autosomal dominant disease is characterized by markedly elevated plasma concentrations of low density lipoprotein (LDL) and total cholesterol (TC). The purpose of this study is to compare the effect of a diet low in saturated fats but enriched either with rapeseed oil (RO) or sunflower oil (SO) in children and adolescents with FH on serum lipoproteins.

Interventions

DIETARY_SUPPLEMENTrapeseed oil

rapeseed oil in amounts between 14 and 27 g

DIETARY_SUPPLEMENTsunflower oil

sunflower oil

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* chilren and adolescents between 6 and 18 years of age * LDLc \> 130 mg/dl and * TC \> 200 mg/dl * 7 day nutrition record * written informed consent

Exclusion criteria

* overweight * underweight * mental disability * drug therapy

Design outcomes

Primary

MeasureTime frame
Blood analysis including fasting serum lipoproteins (TC, LDLc; HDLc; TG, Lp(a), Apolipoprotein A-1, Apolipoprotein B, BB, hs-CRP, GOT, GPT, GGT, acid composition of plasma lipids.done in Week 1, Week 7, Week 13

Secondary

MeasureTime frame
Motivation, compliance, increase of quality of life.done in Week 1 and Week 13
Acceptance and approach to the disease.done in Week 1 and Week 13
Improvement of knowledge and understanding about the disease by the patients.done in Week 1 and Week 13

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026